Avexis, Inc.

Home » Avexis, Inc.

Secondary

Avexis, Inc.

They are a clinical-stage gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases.

Symbol

AVXS

Last Closing Price
$105.01

Shares
3,400,000

Effective Date
January 17, 2018

Underwriters
Goldman Sachs & Co., Jefferies, BofA Merrill Lynch

To view the prospectus for Avexis, Inc., or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253